Cargando…
Studies of the in vivo and in vitro cytotoxicity of the drug RSU-1069.
The radiosensitizing and cytotoxic properties of the drug RSU-1069, (1-(2-nitro-1-imidazolyl)-3-(1-aziridino)-2-propanol) a 2-nitroimidazole with an aziridine ring in its side-chain, have been examined both in vivo and in vitro. Studies with the KHT Sarcoma or RIF1 tumour indicated that, at doses be...
Autores principales: | Hill, R. P., Gulyas, S., Whitmore, G. F. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1986
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001407/ https://www.ncbi.nlm.nih.gov/pubmed/3755053 |
Ejemplares similares
-
Potentiation of RSU-1069 tumour cytotoxicity by 5-hydroxytryptamine (5-HT).
por: Chaplin, D. J.
Publicado: (1986) -
Distribution of pimonidazole and RSU 1069 in tumour and normal tissues.
por: Cobb, L. M., et al.
Publicado: (1990) -
Radiation sensitization and chemopotentiation: RSU 1069, a compound more efficient than misonidazole in vitro and in vivo.
por: Adams, G. E., et al.
Publicado: (1984) -
Pharmacokinetics and cytotoxicity of RSU-1069 in subcutaneous 9L tumours under oxic and hypoxic conditions.
por: Wong, K. H., et al.
Publicado: (1991) -
The differential cytotoxicity of RSU 1069: cell survival studies indicating interaction with DNA as a possible mode of action.
por: Stratford, I. J., et al.
Publicado: (1986)